Clinical Trials Browser

Phase 1 × Recruiting × darolutamide × Clear all

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT05997615 2026-02-24

AMX-500

Phase 1 Recruiting

390 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Phase 1 Recruiting

277 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Phase 1 Recruiting

30 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Recruiting

60 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05519449 2026-01-20

ENGAGER-PSMA-01

Phase 1 Recruiting

272 enrolled

Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

STRIKE-001

AMX-500

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

ENGAGER-PSMA-01

Study of ORIC-944 in Patients With Metastatic Prostate Cancer